Plasminogen intravenous - ProMetic Life Sciences

Drug Profile

Plasminogen intravenous - ProMetic Life Sciences

Alternative Names: Ryplazim; Ryplazima

Latest Information Update: 03 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProMetic Life Sciences
  • Class Anti-inflammatories; Antithrombotics; Beta-globulins; Blood products and substitutes; Proteins
  • Mechanism of Action Plasminogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Type I plasminogen deficiency
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Type I plasminogen deficiency
  • Preclinical Acute lung injury; Idiopathic pulmonary fibrosis; Wounds

Most Recent Events

  • 18 Dec 2017 Plasminogen intravenous - ProMetic Life Sciences receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA
  • 09 Dec 2017 Updated efficacy data from phase II/III trial in Type-1 plasminogen deficiency presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
  • 19 Oct 2017 Intranasal plasminogen receives priority review status for Type-I Plasminogen Deficiency in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top